InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 7,186 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,186 shares of the firm’s stock in a transaction on Friday, May 30th. The stock was sold at an average price of $2.51, for a total value of $18,036.86. Following the sale, the insider owned 1,079,601 shares in the company, valued at $2,709,798.51. This trade represents a 0.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Stock Up 3.0%

Shares of NSPR stock traded up $0.03 during mid-day trading on Thursday, hitting $1.03. 160,140 shares of the company’s stock were exchanged, compared to its average volume of 182,457. InspireMD, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $2.93. The stock has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $1.68. The stock has a market cap of $48.24 million, a price-to-earnings ratio of -1.37 and a beta of 0.82.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Loop Capital set a $5.00 price objective on InspireMD in a report on Tuesday, February 24th. Maxim Group assumed coverage on InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $4.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of InspireMD in the 4th quarter worth $30,000. Renaissance Technologies LLC acquired a new position in shares of InspireMD in the first quarter worth about $29,000. Virtu Financial LLC purchased a new position in InspireMD in the fourth quarter valued at about $31,000. Creative Planning purchased a new position in InspireMD in the second quarter valued at about $44,000. Finally, Uniting Wealth Partners LLC purchased a new position in InspireMD in the third quarter valued at about $51,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.